Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で96.84%の成長率を示しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD 53.51Mです。%!(EXTRA int=2)
割安
同社の最新のPEは44.76で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は35.48M株で、前四半期比で12.16%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を3.20M株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は1.56です。